Funk, TjedePharris, AnastasiaSpiteri, GianfrancoBundle, NickMelidou, AngelikiCarr, MichaelGonzalez, GabrielGarcia-Leon, AlejandroCrispie, FionaO’Connor, LoisMurphy, NiamhMossong, JoëlVergison, AnneWienecke-Baldacchino, Anke K.Abdelrahman, TamirRiccardo, FlaviaStefanelli, PaolaDi Martino, AngelaBella, AntoninoLo Presti, AlessandraCasaca, PedroMoreno, JoanaBorges, VítorIsidro, JoanaFerreira, RitaGomes, João PauloDotsenko, LiidiaSuija, HeleeneEpstein, JevgeniaSadikova, OlgaSepp, HannaIkonen, NiinaSavolainen-Kopra, CaritaBlomqvist, SoileMöttönen, TeemuHelve, OttoGomes-Dias, JoanaAdlhoch, Cornelia2022-07-052022-07-052021-04Euro Surveill. 2021 Apr;26(16):2100348. doi: 10.2807/1560-7917.ES.2021.26.16.21003481560-7917http://hdl.handle.net/10400.18/8060COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs.We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8).engCOVID-19EuropeSARS-CoV-2SurveillanceVariants of ConcernInfecções Respiratóriasjournal article10.2807/1560-7917.ES.2021.26.16.2100348